Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.

Theranostics · 2020 · PMC7052896 · PMID 32194826

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Administration of hcAbs showed a trend toward stronger inhibition of tumor cell growth as compared to daratumumab, however without reaching a statistically significant difference (all p>0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.